colorbar
Help ensure YOUR PATIENTS HAVE ACCESS TO SUSTOL
SUSTOL Connect and patient supportn
Patient Support
For your patients

SUSTOL Copay Assistance Program*

  • Eligible patients pay $0 in out-of-pocket costs with the SUSTOL Copay Assistance Program
    • No physical copay card is required
    • Copay reimbursement will be offered directly to your practice
    • Through SUSTOL Connect™, Reimbursement Counselors will provide information on financial assistance options and help with program enrollment for eligible patients

SUSTOL Patient Assistance Program

  • SUSTOL can be provided at no cost to patients with financial hardship who meet program eligibility criteria
  • Depending on your patient’s financial situation and clinical status, resources may be available to help with your patient’s costs for SUSTOL
  • Through SUSTOL Connect™, experienced Reimbursement Counselors will:
    • Provide information on financial assistance options and eligibility determination
    • If eligible, they will assist with enrollment and coordination to obtain product free of cost

Contact SUSTOL Connect

  • For information on how to access SUSTOL, call 1-855-SUSTOL-6 (1-855-787-8656), 8 am to 8 pm ET, Monday through Friday
  • To benefit from programs offered by SUSTOL Connect™, a completed patient program enrollment form should be submitted by fax to 1-844-504-8652, and in most cases, results will be provided within 2 business days
*Limitations apply. Offer not valid as follows: (a) patients covered under Medicare, Medicaid, or any federal or state program; (b) where plan covers treatment for the patient for the entire cost of the prescription drug or; (c) towards the patient’s deductible. Patients pay $0 copay per dose per 12-month calendar period. For cash-paying patients, the program will cover $150 per prescription, up to $1,800 per calendar year. Eligibility is for 12 months, after which patient will need to reapply for continued assistance. This offer expires 12-31-17.
Heron Therapeutics reserves the right, at its sole discretion, to discontinue the Patient Assistance Program or change the qualifications at any time. All patient information remains confidential. Product supply for the program depends on availability.
Patient Resources
SUSTOL Insurance verification enrollment program form
Insurance Verification and Program Enrollment Form
One single form used to verify benefits and enroll patients in SUSTOL Connect™ Programs.

 

SUSTOL Patient Brochure: SUSTOL provides you with protection that lasts
Patient Education Brochure
A brochure that you can use to educate your patients about CINV and why SUSTOL was prescribed for them.

Indication

SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens.

Important Safety Information

Contraindications

SUSTOL is contraindicated in patients with hypersensitivity to granisetron, any of the components of SUSTOL, or any other 5-HT3 receptor antagonist.

Warnings and Precautions

Injection site reactions (ISRs), including infection, bleeding, pain and tenderness, nodules, swelling, and induration, have occurred with SUSTOL. Monitor for ISRs following SUSTOL injection. Inform patients that some ISRs may occur 2 weeks or more after SUSTOL administration. In patients receiving antiplatelet agents or anticoagulants, consider the increased risk of bruising or severe hematoma prior to the use of SUSTOL.

Monitor for constipation and decreased bowel activity and consider optimizing patients’ current bowel regimens used for managing preexisting constipation. Instruct patients to seek immediate medical care if signs and symptoms of ileus occur.

Hypersensitivity reactions have been reported and may occur up to 7 days or longer following SUSTOL administration and may have an extended course. If a reaction occurs, administer appropriate treatment and monitor until signs and symptoms resolve.

Serotonin syndrome has been reported with 5-HT3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs.

Use in Specific Populations

Avoid SUSTOL in patients with severe renal impairment. In patients with moderate renal impairment, administer SUSTOL not more frequently than once every 14 days.

Adverse Reactions

Most common adverse reactions (≥3%) are injection site reactions, constipation, fatigue, headache, diarrhea, abdominal pain, insomnia, dyspepsia, dizziness, asthenia, and gastroesophageal reflux.

For more information about SUSTOL, please see full Prescribing Information.





Indication

SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens.

Important Safety Information

Contraindications

SUSTOL is contraindicated in patients with hypersensitivity to granisetron, any of the components of SUSTOL, or any other 5-HT3 receptor antagonist.

Warnings and Precautions

Injection site reactions (ISRs), including infection, bleeding, pain and tenderness, nodules, swelling, and induration, have occurred with SUSTOL. Monitor for ISRs following SUSTOL injection. Inform patients that some ISRs may occur 2 weeks or more after SUSTOL administration. In patients receiving antiplatelet agents or anticoagulants, consider the increased risk of bruising or severe hematoma prior to the use of SUSTOL.

Monitor for constipation and decreased bowel activity and consider optimizing patients’ current bowel regimens used for managing preexisting constipation. Instruct patients to seek immediate medical care if signs and symptoms of ileus occur.

Hypersensitivity reactions have been reported and may occur up to 7 days or longer following SUSTOL administration and may have an extended course. If a reaction occurs, administer appropriate treatment and monitor until signs and symptoms resolve.

Serotonin syndrome has been reported with 5-HT3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs.

Use in Specific Populations

Avoid SUSTOL in patients with severe renal impairment. In patients with moderate renal impairment, administer SUSTOL not more frequently than once every 14 days.

Adverse Reactions

Most common adverse reactions (≥3%) are injection site reactions, constipation, fatigue, headache, diarrhea, abdominal pain, insomnia, dyspepsia, dizziness, asthenia, and gastroesophageal reflux.

For more information about SUSTOL, please see full Prescribing Information.